Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of 5FU-Based Therapy + Hydroxytyrosol in Advanced/Metastatic Colorectal Cancer
NCT06833866Phase 1Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Dec 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydroxytyrosol in colorectal cancer (CRC), sponsored by Houston Methodist Research Institute. Primary endpoint: Safety, Toxicity, and Pharmacokinetic/Pharmacodynamic Profile up to 2 years. Started Dec 2024; status: recruiting.
02
Drugs
hydroxytyrosol
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06833866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06833866.